Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akoya Biosciences, Inc.
Report date July 08, 2025 · Filed July 10, 2025
Section 16 reporting ended · disclosed 2025-07-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectThomas A. Raffin Living Trust dated March 29, 2017 | 0 |
Reported balance
After 2025-07-08 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-07-08 · Other · Disposed 234,592 · Balance 0 F1: Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix. F2: In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote 3 | 0 |
Reported balance
After 2025-07-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-07-08 · Other · Disposed 1,737,712 · Balance 0 F1: Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix. F2: In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement. F3: Shares held directly by THP III Affiliates Fund, LLC ("THP III AFF"). Telegraph Hill Partners III Investment Management, LLC ("THP IM") is the manager of THP III AFF. Telegraph Hill Partners Management Company, LLC ("THPMC") is the manager of THP IM. J. Matthew Mackowski, Dr. Thomas A. Raffin and Deval Lashkari are each managers of THPMC and may be deemed to share voting and dispositive power over the securities held by THP III AFF. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote 4 | 0 |
Reported balance
After 2025-07-08 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-07-08 · Other · Disposed 15,937,535 · Balance 0 F1: Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix. F2: In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement. F4: Shares held directly by Telegraph Hill Partners III, L.P. ("THP III"). THP IM is the general partner of THP III. THPMC is the manager of THP IM. J. Matthew Mackowski, Dr. Thomas A. Raffin and Deval Lashkari are each managers of THPMC and may be deemed to share voting and dispositive power over the securities held by THP III. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.95 · Expires 2031-05-21 | Direct | 0 |
Reported balance
After 2025-07-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-08 · Other · Disposed 16,860 · Balance 0 F5: Disposition of options pursuant to Merger Agreement. F6: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.24 · Expires 2032-06-01 | Direct | 0 |
Reported balance
After 2025-07-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-08 · Other · Disposed 30,549 · Balance 0 F5: Disposition of options pursuant to Merger Agreement. F6: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.70 · Expires 2033-06-01 | Direct | 0 |
Reported balance
After 2025-07-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-07-08 · Other · Disposed 56,322 · Balance 0 F5: Disposition of options pursuant to Merger Agreement. F6: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2034-06-04 | Direct | 0 |
Reported balance
After 2025-07-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-07-08 · Other · Disposed 50,000 · Balance 0 F5: Disposition of options pursuant to Merger Agreement. F6: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.
F2: In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.
F3: Shares held directly by THP III Affiliates Fund, LLC ("THP III AFF"). Telegraph Hill Partners III Investment Management, LLC ("THP IM") is the manager of THP III AFF. Telegraph Hill Partners Management Company, LLC ("THPMC") is the manager of THP IM. J. Matthew Mackowski, Dr. Thomas A. Raffin and Deval Lashkari are each managers of THPMC and may be deemed to share voting and dispositive power over the securities held by THP III AFF. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F4: Shares held directly by Telegraph Hill Partners III, L.P. ("THP III"). THP IM is the general partner of THP III. THPMC is the manager of THP IM. J. Matthew Mackowski, Dr. Thomas A. Raffin and Deval Lashkari are each managers of THPMC and may be deemed to share voting and dispositive power over the securities held by THP III. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F5: Disposition of options pursuant to Merger Agreement.
F6: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.
LUMOS PHARMA, INC.
Report date December 12, 2024 · Filed December 13, 2024
Section 16 reporting ended · disclosed 2024-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 1
1 source rowRow 1 · 2024-12-12 · Disposition to issuer · Disposed 9,406 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated October 22, 2024, by and between the Issuer, DPV Parent, Inc., DPV MergerSub, Inc. and Double Point Ventures LLC ("DPV") (the "Merger Agreement") in exchange for (i) $4.25 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2033-05-09 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-12 · Disposition to issuer · Disposed 3,345 · Balance 0 F2: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.35 · Expires 2034-06-04 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-12-12 · Disposition to issuer · Disposed 3,328 · Balance 0 F2: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2030-04-02 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-12-12 · Disposition to issuer · Disposed 5,684 · Balance 0 F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.18 · Expires 2032-05-04 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-12-12 · Disposition to issuer · Disposed 3,431 · Balance 0 F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.36 · Expires 2031-05-19 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-12-12 · Disposition to issuer · Disposed 2,910 · Balance 0 F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.21 · Expires 2029-05-09 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-12-12 · Disposition to issuer · Disposed 2,777 · Balance 0 F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.93 · Expires 2026-07-31 | Direct | 0 |
Reported balance
After 2024-12-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-12-12 · Disposition to issuer · Disposed 10,439 · Balance 0 F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated October 22, 2024, by and between the Issuer, DPV Parent, Inc., DPV MergerSub, Inc. and Double Point Ventures LLC ("DPV") (the "Merger Agreement") in exchange for (i) $4.25 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share.
F2: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash equal to the product of (x) the total number of shares underlying such option multiplied by (y) the excess of the Cash Amount over the applicable exercise price per share and (ii) one CVR for each share underlying such in-the-money option.
F3: Represents an out-of-money option that was cancelled without any cash payment or issuance of CVRs being made in respect thereof pursuant to the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2019 Filed Aug 2, 2019 18:37 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 8,929 | Not disclosed Strike: $1.77 | Not disclosed |
DisclosureSEC source: 0001126234-19-000099 · wf-form4_156478543324927.xml · derivative · entry 4 Raffin Thomas A. · CIK 0001512119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,929 Underlying: Common Stock · 8,929 shares Expires 2026-07-31 F1 · price: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. F2 · derivative.exercise_date: The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 18:37 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,857 | Not disclosed Strike: $10.02 | Not disclosed |
DisclosureSEC source: 0001126234-19-000099 · wf-form4_156478543324927.xml · derivative · entry 3 Raffin Thomas A. · CIK 0001512119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,857 shares Expires 2020-12-08 F1 · price: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 18:37 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 13,095 | Not disclosed Strike: $1.77 | Not disclosed |
DisclosureSEC source: 0001126234-19-000099 · wf-form4_156478543324927.xml · derivative · entry 2 Raffin Thomas A. · CIK 0001512119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,095 Underlying: Common Stock · 13,095 shares Expires 2026-07-31 F1 · price: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. F2 · derivative.exercise_date: The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 18:37 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,190 | Not disclosed Strike: $3.07 | Not disclosed |
DisclosureSEC source: 0001126234-19-000099 · wf-form4_156478543324927.xml · derivative · entry 1 Raffin Thomas A. · CIK 0001512119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,190 shares Expires 2020-03-02 F1 · price: On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program. In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share. Read SEC document |
| May 10, 2019 Filed May 14, 2019 17:32 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001126234-19-000057 · wf-form4_155786955720528.xml · derivative · entry 1 Raffin Thomas A. · CIK 0001512119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-05-09 F1 · derivative.exercise_date: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan, as amended (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant. Read SEC document |
| May 23, 2018 Filed May 25, 2018 18:01 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 27,777 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001126234-18-000101 · wf-form4_152728565933634.xml · derivative · entry 1 Raffin Thomas A. · CIK 0001512119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,777 Underlying: Common Stock · 27,777 shares Expires 2028-05-22 F1 · derivative.exercise_date: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant. Read SEC document |
| May 12, 2017 Filed May 16, 2017 17:20 UTC | LUMOS PHARMA, INC. (NLNK) · Entity 85102 | GrantStock Option (Right to Buy) · Derivative | 13,309 | $0.00 Strike: $17.42 | $0.00 |
DisclosureSEC source: 0001126234-17-000053 · wf-form4_149496964466627.xml · derivative · entry 1 Raffin Thomas A. · CIK 0001512119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,309 Underlying: Common Stock · 13,309 shares Expires 2027-05-11 F1 · derivative.exercise_date: Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the "Plan"). One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date. The option expires ten years after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.